Diversity in Antioxidant Response Enzymes in Progressive Stages of Human Nonalcoholic Fatty Liver Disease
Nonalcoholic fatty liver disease (NAFLD), which occurs in approximately 17 to 40% of Americans, encompasses progressive stages of liver damage ranging from steatosis to nonalcoholic steatohepatitis (NASH). Inflammation and oxidative stress are known characteristics of NAFLD; however, the precise mec...
Saved in:
Published in | Drug metabolism and disposition Vol. 38; no. 12; pp. 2293 - 2301 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
Bethesda, MD
Elsevier Inc
01.12.2010
American Society for Pharmacology and Experimental Therapeutics The American Society for Pharmacology and Experimental Therapeutics |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Nonalcoholic fatty liver disease (NAFLD), which occurs in approximately 17 to 40% of Americans, encompasses progressive stages of liver damage ranging from steatosis to nonalcoholic steatohepatitis (NASH). Inflammation and oxidative stress are known characteristics of NAFLD; however, the precise mechanisms occurring during disease progression remain unclear. The purpose of the current study was to determine whether the expression or function of enzymes involved in the antioxidant response, NAD(P)H:quinone oxidoreductase 1 (NQO1), glutathione transferase (GST), and glutamate cysteine ligase, are altered in the progression of human NAFLD. Human livers staged as normal, steatotic, NASH (fatty), and NASH (not fatty) were obtained from the Liver Tissue Cell Distribution System. NQO1 mRNA, protein, and activity tended to increase with disease progression. mRNA levels of the GST isoforms A1, A2, A4, M3, and P1 increased with NAFLD progression. Likewise, GST A and P protein increased with progression; however, GST M protein levels tended to decrease. Of interest, total GST activity toward the substrate 1-chloro-2,4-dinitrobenzene decreased with NAFLD progression. GSH synthesis does not seem to be significantly dysregulated in NAFLD progression; however, the GSH/oxidized glutathione redox ratio seemed to be reduced with disease severity, indicating the presence of oxidative stress and depletion of GSH throughout progression of NAFLD. Malondialdehyde concentrations were significantly increased with disease progression, further indicating the presence of oxidative stress. Nuclear immunohistochemical staining of nuclear factor E2-related factor 2 (Nrf2), an indicator of activation of the transcription factor, was evident in all stages of NAFLD. The current data suggest that Nrf2 activation occurs in response to disease progression followed by induction of specific Nrf2 targets, whereas functionality of specific antioxidant defense enzymes seems to be impaired as NAFLD progresses. |
---|---|
AbstractList | Nonalcoholic fatty liver disease (NAFLD), which occurs in approximately 17 to 40% of Americans, encompasses progressive stages of liver damage ranging from steatosis to nonalcoholic steatohepatitis (NASH). Inflammation and oxidative stress are known characteristics of NAFLD; however, the precise mechanisms occurring during disease progression remain unclear. The purpose of the current study was to determine whether the expression or function of enzymes involved in the antioxidant response, NAD(P)H:quinone oxidoreductase 1 (NQO1), glutathione transferase (GST), and glutamate cysteine ligase, are altered in the progression of human NAFLD. Human livers staged as normal, steatotic, NASH (fatty), and NASH (not fatty) were obtained from the Liver Tissue Cell Distribution System. NQO1 mRNA, protein, and activity tended to increase with disease progression. mRNA levels of the GST isoforms A1, A2, A4, M3, and P1 increased with NAFLD progression. Likewise, GST A and P protein increased with progression; however, GST M protein levels tended to decrease. Of interest, total GST activity toward the substrate 1-chloro-2,4-dinitrobenzene decreased with NAFLD progression. GSH synthesis does not seem to be significantly dysregulated in NAFLD progression; however, the GSH/oxidized glutathione redox ratio seemed to be reduced with disease severity, indicating the presence of oxidative stress and depletion of GSH throughout progression of NAFLD. Malondialdehyde concentrations were significantly increased with disease progression, further indicating the presence of oxidative stress. Nuclear immunohistochemical staining of nuclear factor E2-related factor 2 (Nrf2), an indicator of activation of the transcription factor, was evident in all stages of NAFLD. The current data suggest that Nrf2 activation occurs in response to disease progression followed by induction of specific Nrf2 targets, whereas functionality of specific antioxidant defense enzymes seems to be impaired as NAFLD progresses.Nonalcoholic fatty liver disease (NAFLD), which occurs in approximately 17 to 40% of Americans, encompasses progressive stages of liver damage ranging from steatosis to nonalcoholic steatohepatitis (NASH). Inflammation and oxidative stress are known characteristics of NAFLD; however, the precise mechanisms occurring during disease progression remain unclear. The purpose of the current study was to determine whether the expression or function of enzymes involved in the antioxidant response, NAD(P)H:quinone oxidoreductase 1 (NQO1), glutathione transferase (GST), and glutamate cysteine ligase, are altered in the progression of human NAFLD. Human livers staged as normal, steatotic, NASH (fatty), and NASH (not fatty) were obtained from the Liver Tissue Cell Distribution System. NQO1 mRNA, protein, and activity tended to increase with disease progression. mRNA levels of the GST isoforms A1, A2, A4, M3, and P1 increased with NAFLD progression. Likewise, GST A and P protein increased with progression; however, GST M protein levels tended to decrease. Of interest, total GST activity toward the substrate 1-chloro-2,4-dinitrobenzene decreased with NAFLD progression. GSH synthesis does not seem to be significantly dysregulated in NAFLD progression; however, the GSH/oxidized glutathione redox ratio seemed to be reduced with disease severity, indicating the presence of oxidative stress and depletion of GSH throughout progression of NAFLD. Malondialdehyde concentrations were significantly increased with disease progression, further indicating the presence of oxidative stress. Nuclear immunohistochemical staining of nuclear factor E2-related factor 2 (Nrf2), an indicator of activation of the transcription factor, was evident in all stages of NAFLD. The current data suggest that Nrf2 activation occurs in response to disease progression followed by induction of specific Nrf2 targets, whereas functionality of specific antioxidant defense enzymes seems to be impaired as NAFLD progresses. Nonalcoholic fatty liver disease (NAFLD), which occurs in approximately 17 to 40% of Americans, encompasses progressive stages of liver damage ranging from steatosis to nonalcoholic steatohepatitis (NASH). Inflammation and oxidative stress are known characteristics of NAFLD; however, the precise mechanisms occurring during disease progression remain unclear. The purpose of the current study was to determine whether the expression or function of enzymes involved in the antioxidant response, NAD(P)H:quinone oxidoreductase 1 (NQO1), glutathione transferase (GST), and glutamate cysteine ligase, are altered in the progression of human NAFLD. Human livers staged as normal, steatotic, NASH (fatty), and NASH (not fatty) were obtained from the Liver Tissue Cell Distribution System. NQO1 mRNA, protein, and activity tended to increase with disease progression. mRNA levels of the GST isoforms A1, A2, A4, M3, and P1 increased with NAFLD progression. Likewise, GST A and P protein increased with progression; however, GST M protein levels tended to decrease. Of interest, total GST activity toward the substrate 1-chloro-2,4-dinitrobenzene decreased with NAFLD progression. GSH synthesis does not seem to be significantly dysregulated in NAFLD progression; however, the GSH/oxidized glutathione redox ratio seemed to be reduced with disease severity, indicating the presence of oxidative stress and depletion of GSH throughout progression of NAFLD. Malondialdehyde concentrations were significantly increased with disease progression, further indicating the presence of oxidative stress. Nuclear immunohistochemical staining of nuclear factor E2-related factor 2 (Nrf2), an indicator of activation of the transcription factor, was evident in all stages of NAFLD. The current data suggest that Nrf2 activation occurs in response to disease progression followed by induction of specific Nrf2 targets, whereas functionality of specific antioxidant defense enzymes seems to be impaired as NAFLD progresses. Nonalcoholic fatty liver disease (NAFLD), which occurs in approximately 17 to 40% of Americans, encompasses progressive stages of liver damage ranging from steatosis to nonalcoholic steatohepatitis (NASH). Inflammation and oxidative stress are known characteristics of NAFLD; however, the precise mechanisms occurring during disease progression remain unclear. The purpose of the current study was to determine whether the expression or function of enzymes involved in the antioxidant response, NAD(P)H:quinone oxidoreductase 1 (NQO1), glutathione transferase (GST), and glutamate cysteine ligase, are altered in the progression of human NAFLD. Human livers staged as normal, steatotic, NASH (fatty), and NASH (not fatty) were obtained from the Liver Tissue Cell Distribution System. NQO1 mRNA, protein, and activity tended to increase with disease progression. mRNA levels of the GST isoforms A1, A2, A4, M3, and P1 increased with NAFLD progression. Likewise, GST A and P protein increased with progression; however, GST M protein levels tended to decrease. Of interest, total GST activity toward the substrate 1-chloro-2,4-dinitrobenzene decreased with NAFLD progression. GSH synthesis does not seem to be significantly dysregulated in NAFLD progression; however, the GSH/oxidized glutathione redox ratio seemed to be reduced with disease severity, indicating the presence of oxidative stress and depletion of GSH throughout progression of NAFLD. Malondialdehyde concentrations were significantly increased with disease progression, further indicating the presence of oxidative stress. Nuclear immunohistochemical staining of nuclear factor E2-related factor 2 (Nrf2), an indicator of activation of the transcription factor, was evident in all stages of NAFLD. The current data suggest that Nrf2 activation occurs in response to disease progression followed by induction of specific Nrf2 targets, whereas functionality of specific antioxidant defense enzymes seems to be impaired as NAFLD progresses. |
Author | Fisher, Craig D. Hardwick, Rhiannon N. Canet, Mark J. Lake, April D. Cherrington, Nathan J. |
Author_xml | – sequence: 1 givenname: Rhiannon N. surname: Hardwick fullname: Hardwick, Rhiannon N. – sequence: 2 givenname: Craig D. surname: Fisher fullname: Fisher, Craig D. – sequence: 3 givenname: Mark J. surname: Canet fullname: Canet, Mark J. – sequence: 4 givenname: April D. surname: Lake fullname: Lake, April D. – sequence: 5 givenname: Nathan J. surname: Cherrington fullname: Cherrington, Nathan J. email: cherrington@pharmacy.arizona.edu |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=23597686$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/20805291$$D View this record in MEDLINE/PubMed |
BookMark | eNp1UU1rGzEQFSWlcdJeeyx7KT2tK62kXelSCPkG05Z-QG9CK806KruSI8mm7q-vjJ1-QU5vmHnvzTDvBB354AGhlwTPCWnYWzvZUuA5phzj9gmaEd6QGmP57QjNCuBact4eo5OUvmNMGKPyGTpusMC8kWSG3IXbQEwubyvnqzOfXfjhrPa5-gRpFXyC6tL_3E6QdvOPMSwjpFQ01eesl6UbhupmPWlfvQ9ejybchdGZ6krn4rjYeVcXLoFO8Bw9HfSY4MUBT9HXq8sv5zf14sP17fnZojasFbk2PWbUyKYVtEAvZWctl9pIIWWjDbFMU94XNJ3tGR5a0fVci0Z2hDI2WHqK3u19V-t-AmvA56hHtYpu0nGrgnbq34l3d2oZNqqRkjLOisGbg0EM92tIWU0uGRhH7SGskxJYsLbcKgrz1d-rfu94eG8hvD4QdDJ6HKL2xqU_PMpl14q28NieZ2JIKcKgjMu6ZLG70I2KYLVLW5W0S4HVPu0im_8ne3B-VCD2AigBbBxElYwDb8C6CCYrG9xj0l9BScCa |
CODEN | DMDSAI |
CitedBy_id | crossref_primary_10_1124_dmd_117_077644 crossref_primary_10_1538_expanim_16_0010 crossref_primary_10_3390_antiox10081222 crossref_primary_10_1124_dmd_114_062703 crossref_primary_10_3109_03602532_2011_558092 crossref_primary_10_1016_j_jhep_2012_11_014 crossref_primary_10_1093_toxsci_kft275 crossref_primary_10_1016_j_fbio_2024_104142 crossref_primary_10_1016_j_lfs_2024_122806 crossref_primary_10_3390_antiox7010012 crossref_primary_10_1016_j_ajpath_2016_03_005 crossref_primary_10_3389_fmed_2021_595371 crossref_primary_10_1186_s12864_023_09160_4 crossref_primary_10_3109_13880209_2015_1060247 crossref_primary_10_1016_j_freeradbiomed_2015_12_014 crossref_primary_10_1038_labinvest_2017_22 crossref_primary_10_1016_j_jhep_2011_05_019 crossref_primary_10_1016_j_mehy_2011_05_034 crossref_primary_10_1124_dmd_116_071415 crossref_primary_10_1016_j_mri_2016_03_009 crossref_primary_10_1186_s12906_017_1762_8 crossref_primary_10_1080_13102818_2019_1674690 crossref_primary_10_3390_antiox9070578 crossref_primary_10_1038_s41598_018_24403_1 crossref_primary_10_1038_srep34719 crossref_primary_10_1007_s00394_015_0877_2 crossref_primary_10_1139_cjpp_2014_0394 crossref_primary_10_1124_dmd_121_000413 crossref_primary_10_3390_antiox13111371 crossref_primary_10_1002_psp4_12185 crossref_primary_10_1371_journal_pone_0143121 crossref_primary_10_1038_nrd_2015_3 crossref_primary_10_1002_hep_26925 crossref_primary_10_1371_journal_pone_0096553 crossref_primary_10_1124_dmd_112_046177 crossref_primary_10_5812_hepatmon_9527 crossref_primary_10_3390_biomedicines8090350 crossref_primary_10_3390_antiox10081289 crossref_primary_10_1111_apt_14952 crossref_primary_10_1124_dmd_113_055996 crossref_primary_10_1007_s11745_015_4084_y crossref_primary_10_1016_j_freeradbiomed_2013_08_174 crossref_primary_10_1016_j_taap_2024_117185 crossref_primary_10_1111_j_1440_1746_2012_07255_x crossref_primary_10_3389_fendo_2020_607011 crossref_primary_10_1016_j_bbadis_2018_10_010 crossref_primary_10_3390_antiox9100980 crossref_primary_10_1538_expanim_17_0112 crossref_primary_10_2337_db14_1947 crossref_primary_10_3390_ijms19072034 crossref_primary_10_1111_1440_1681_12040 crossref_primary_10_1038_labinvest_2014_3 crossref_primary_10_1007_s00204_024_03889_x crossref_primary_10_1179_1351000213Y_0000000050 crossref_primary_10_1016_j_jtcme_2017_05_006 crossref_primary_10_1007_s11095_013_1140_2 crossref_primary_10_1016_j_taap_2019_02_009 crossref_primary_10_4254_wjh_v17_i2_101741 crossref_primary_10_3390_livers3010003 crossref_primary_10_1016_j_taap_2019_114664 crossref_primary_10_1139_cjpp_2016_0681 crossref_primary_10_1111_bcp_12802 crossref_primary_10_3390_ijerph16224334 crossref_primary_10_1089_jmf_2021_K_0090 crossref_primary_10_1080_13510002_2018_1546985 crossref_primary_10_1038_s41598_020_65481_4 crossref_primary_10_1002_hep_30368 crossref_primary_10_1177_0960327113506723 crossref_primary_10_1016_j_fct_2017_02_039 crossref_primary_10_1124_dmd_111_040592 crossref_primary_10_5937_mp70_17890 crossref_primary_10_3390_antiox11030447 crossref_primary_10_4161_cc_20259 crossref_primary_10_1093_toxsci_kft230 crossref_primary_10_1002_jcph_768 crossref_primary_10_1007_s13318_020_00666_w crossref_primary_10_1016_j_cyto_2018_10_010 crossref_primary_10_3389_fimmu_2022_870239 crossref_primary_10_1016_j_csbj_2018_10_013 crossref_primary_10_1124_dmd_111_041095 crossref_primary_10_3390_receptors2010001 crossref_primary_10_1016_j_cbi_2018_04_010 crossref_primary_10_1186_s13023_017_0689_y crossref_primary_10_3390_nu13103334 crossref_primary_10_4254_wjh_v7_i27_2749 crossref_primary_10_1007_s12072_020_10112_3 crossref_primary_10_1124_dmd_111_041012 crossref_primary_10_1016_j_pharmthera_2015_03_005 crossref_primary_10_1007_s11095_022_03295_x crossref_primary_10_1016_j_taap_2013_01_022 crossref_primary_10_1124_jpet_114_220764 crossref_primary_10_1016_j_metabol_2017_04_011 crossref_primary_10_1093_toxsci_kfu156 crossref_primary_10_1517_17425255_2014_936378 crossref_primary_10_1089_ars_2013_5486 crossref_primary_10_1089_ars_2016_6776 crossref_primary_10_3109_10715762_2013_837577 crossref_primary_10_1111_hepr_12992 crossref_primary_10_1016_j_cca_2011_04_013 crossref_primary_10_1124_dmd_112_048439 crossref_primary_10_1139_cjpp_2019_0383 crossref_primary_10_1124_jpet_116_238790 crossref_primary_10_1016_j_jbior_2018_11_004 crossref_primary_10_3389_fendo_2023_1050049 crossref_primary_10_1016_j_jhep_2014_02_021 crossref_primary_10_1155_2015_597134 crossref_primary_10_1093_toxsci_kfx253 crossref_primary_10_3892_etm_2013_1434 crossref_primary_10_1586_17446651_2014_938053 crossref_primary_10_1016_j_freeradbiomed_2021_03_015 crossref_primary_10_1021_acs_chemrestox_0c00131 crossref_primary_10_1016_j_metabol_2013_06_012 crossref_primary_10_1111_liv_13362 crossref_primary_10_1128_MCB_00170_16 crossref_primary_10_3945_ajcn_115_118570 crossref_primary_10_1016_j_foodchem_2025_143956 crossref_primary_10_1124_dmd_113_050930 crossref_primary_10_3945_jn_111_148544 crossref_primary_10_1097_MCO_0b013e328357f747 crossref_primary_10_1080_03602532_2017_1293683 crossref_primary_10_1152_ajpendo_00345_2017 crossref_primary_10_1016_j_freeradbiomed_2022_06_226 crossref_primary_10_1124_dmd_112_049676 crossref_primary_10_1016_S1499_3872_15_60425_8 crossref_primary_10_1089_met_2017_0131 crossref_primary_10_1016_j_bcmd_2011_03_004 crossref_primary_10_1590_0004_2730000002831 crossref_primary_10_1002_jbt_22035 crossref_primary_10_3109_03602532_2011_577781 crossref_primary_10_3168_jds_2012_5900 crossref_primary_10_1089_dna_2011_1343 crossref_primary_10_1124_jpet_118_255018 crossref_primary_10_1155_2023_2877350 crossref_primary_10_1016_j_lfs_2022_120956 crossref_primary_10_3109_10408444_2014_931341 crossref_primary_10_1016_j_jnutbio_2025_109842 crossref_primary_10_1177_0884533612471766 crossref_primary_10_1016_j_etap_2023_104138 crossref_primary_10_1292_jvms_20_0479 crossref_primary_10_1371_journal_pone_0127991 crossref_primary_10_1007_s13273_019_00066_5 crossref_primary_10_1016_j_jff_2016_08_050 |
Cites_doi | 10.1002/jbt.20177 10.1007/s00204-008-0312-z 10.1016/j.freeradbiomed.2004.02.074 10.2133/dmpk.21.437 10.1056/NEJMra011775 10.1016/S0891-5849(00)00306-3 10.1016/j.mrgentox.2008.09.009 10.1016/j.annepidem.2007.05.013 10.1074/mcp.M800070-MCP200 10.2217/14622416.10.1.29 10.1016/S0009-8981(03)00200-6 10.1016/j.canlet.2004.01.003 10.1080/03602530600971974 10.18388/abp.2006_3384 10.1124/dmd.109.027466 10.3748/wjg.v12.i12.1937 10.1006/bbrc.1997.6943 10.1146/annurev.pharmtox.45.120403.095857 10.1681/ASN.2008020227 10.1016/S0076-6879(05)01007-4 10.1074/jbc.M000361200 10.1002/hep.20701 10.1016/S0076-6879(04)82008-1 10.1016/j.molmed.2007.12.003 10.1016/j.tox.2006.11.052 10.1080/07853890802552437 10.1016/S0076-6879(05)01002-5 10.2131/jts.32.453 10.1016/S0009-2797(97)00174-9 10.1080/01926230701311344 10.1016/S0009-2797(97)00096-3 10.1016/S0076-6879(04)82019-6 10.1379/CSC-217.1 10.1016/j.mam.2008.05.005 10.1016/j.bbrc.2007.03.174 |
ContentType | Journal Article |
Copyright | 2010 American Society for Pharmacology and Experimental Therapeutics 2015 INIST-CNRS Copyright © 2010 by The American Society for Pharmacology and Experimental Therapeutics |
Copyright_xml | – notice: 2010 American Society for Pharmacology and Experimental Therapeutics – notice: 2015 INIST-CNRS – notice: Copyright © 2010 by The American Society for Pharmacology and Experimental Therapeutics |
DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7X8 5PM |
DOI | 10.1124/dmd.110.035006 |
DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1521-009X |
EndPage | 2301 |
ExternalDocumentID | PMC2993454 20805291 23597686 10_1124_dmd_110_035006 S0090955624025753 |
Genre | Journal Article Research Support, N.I.H., Extramural |
GrantInformation_xml | – fundername: NLM NIH HHS grantid: HHSN267200700004G – fundername: NIEHS NIH HHS grantid: T32 ES007091 – fundername: NIDDK NIH HHS grantid: DK068039 – fundername: NIDDK NIH HHS grantid: N01-DK-7-0004 – fundername: NLM NIH HHS grantid: HHSN267200700004C – fundername: NIEHS NIH HHS grantid: P30 ES006694 – fundername: NCCIH NIH HHS grantid: F31 AT002842 – fundername: NIEHS NIH HHS grantid: ES006694 – fundername: NIDDK NIH HHS grantid: R01 DK068039 – fundername: NCCIH NIH HHS grantid: AT002842 – fundername: National Institutes of Health grantid: DK068039; ES006694; AT002842; N01-DK-7-0004/HHSN267200700004C |
GroupedDBID | --- .GJ 0R~ 18M 2WC 4.4 53G 5GY 5RE 5VS AAXUO ABJNI ABSQV ACGFO ACGFS ACIWK ACPRK ADBBV AENEX AERNN AFFNX AFOSN AFRAH AI. ALMA_UNASSIGNED_HOLDINGS BAWUL BTFSW CS3 DIK DU5 E3Z EBS EJD F5P F9R FDB GX1 H13 HZ~ IH2 INIJC KQ8 LSO M41 O9- OK1 P2P R0Z RHI ROL RPT SJN TR2 VH1 W8F WH7 WOQ YCJ YHG ZGI ZXP ~KM AALRI AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7X8 5PM |
ID | FETCH-LOGICAL-c468t-cb043c926833c9b997dd59ac98992ac1d4a35bc1dc7db40f687b5a82971344fd3 |
ISSN | 0090-9556 1521-009X |
IngestDate | Thu Aug 21 18:30:46 EDT 2025 Fri Jul 11 04:07:41 EDT 2025 Mon Jul 21 06:01:14 EDT 2025 Mon Jul 21 09:15:36 EDT 2025 Tue Jul 01 05:28:27 EDT 2025 Thu Apr 24 22:51:08 EDT 2025 Sun Apr 06 06:53:03 EDT 2025 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 12 |
Keywords | NQO1 GSSG NAFLD DAB DCPIP GST CDNB TBARS MDA NASH GCL GCLC ARE Nrf2 ROS GCLM HNE ERK Human Clinical stage Enzyme Non alcoholic steatohepatitis Digestive diseases Hepatic disease Antioxidant |
Language | English |
License | CC BY 4.0 |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c468t-cb043c926833c9b997dd59ac98992ac1d4a35bc1dc7db40f687b5a82971344fd3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | https://dmd.aspetjournals.org/content/dmd/38/12/2293.full.pdf |
PMID | 20805291 |
PQID | 808464688 |
PQPubID | 23479 |
PageCount | 9 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_2993454 proquest_miscellaneous_808464688 pubmed_primary_20805291 pascalfrancis_primary_23597686 crossref_citationtrail_10_1124_dmd_110_035006 crossref_primary_10_1124_dmd_110_035006 elsevier_sciencedirect_doi_10_1124_dmd_110_035006 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2010-12-01 |
PublicationDateYYYYMMDD | 2010-12-01 |
PublicationDate_xml | – month: 12 year: 2010 text: 2010-12-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | Bethesda, MD |
PublicationPlace_xml | – name: Bethesda, MD – name: Netherlands |
PublicationTitle | Drug metabolism and disposition |
PublicationTitleAlternate | Drug Metab Dispos |
PublicationYear | 2010 |
Publisher | Elsevier Inc American Society for Pharmacology and Experimental Therapeutics The American Society for Pharmacology and Experimental Therapeutics |
Publisher_xml | – name: Elsevier Inc – name: American Society for Pharmacology and Experimental Therapeutics – name: The American Society for Pharmacology and Experimental Therapeutics |
References | Aleksunes, Slitt, Maher, Dieter, Knight, Goedken, Cherrington, Chan, Klaassen, Manautou (bib4) 2006; 11 Moffit, Aleksunes, Kardas, Slitt, Klaassen, Manautou (bib28) 2007; 230 Kleiner, Brunt, Van Natta, Behling, Contos, Cummings, Ferrell, Liu, Torbenson, Unalp-Arida (bib19) 2005; 41 Martin, Collier, Bowen, Pritsos, Goodrich, Arger, Cutter, Pritsos (bib26) 2009; 674 McCullough (bib27) 2006; 40 Fisher, Jackson, Lickteig, Augustine, Cherrington (bib11) 2008; 82 Adams, Lindor (bib1) 2007; 17 Coles, Kadlubar (bib9) 2005; 401 Henderson, Wolf (bib14) 2005; 401 Lu (bib22) 2009; 30 Sakai, Muramatsu (bib34) 2007; 357 Pastore, Federici, Bertini, Piemonte (bib32) 2003; 333 Clapper, Szarka (bib7) 1998; 111–112 Zhang (bib37) 2006; 38 Marra, Gastaldelli, Svegliati Baroni, Tell, Tiribelli (bib25) 2008; 14 Jaiswal (bib17) 2000; 29 Talalay, Dinkova-Kostova (bib35) 2004; 382 Czeczot, Scibior, Skrzycki, Podsiad (bib10) 2006; 53 Lin, Hung, Wei, Tarng (bib21) 2009; 20 Angulo (bib6) 2002; 346 Nguyen, Huang, Pickett (bib31) 2000; 275 Higashi, Hiai, Higashi, Muramatsu (bib15) 2004; 209 Jaiswal (bib18) 2004; 36 Manfredi, Calvi, del Fiandra, Botto, Biagini, Andreassi (bib23) 2009; 10 van Iersel, Ploemen, Lo Bello, Federici, van Bladeren (bib36) 1997; 108 Nagata, Suzuki, Sakaguchi (bib29) 2007; 32 Ross, Siegel (bib33) 2004; 382 Aleksunes, Manautou (bib3) 2007; 35 Hayes, Flanagan, Jowsey (bib13) 2005; 45 Lickteig, Fisher, Augustine, Cherrington (bib20) 2007; 21 Mannervik, Jemth (bib24) 1999 Nakata, Tanaka, Nakano, Adachi, Tanaka, Kaminuma, Ishikawa (bib30) 2006; 21 Aleksunes, Goedken, Manautou (bib2) 2006; 12 Ali, Cusi (bib5) 2009; 41 Itoh, Chiba, Takahashi, Ishii, Igarashi, Katoh, Oyake, Hayashi, Satoh, Hatayama (bib16) 1997; 236 Fisher, Lickteig, Augustine, Ranger-Moore, Jackson, Ferguson, Cherrington (bib12) 2009; 37 Codreanu, Zhang, Sobecki, Billheimer, Liebler (bib8) 2009; 8 McCullough (10.1124/dmd.110.035006_bib27) 2006; 40 Talalay (10.1124/dmd.110.035006_bib35) 2004; 382 Aleksunes (10.1124/dmd.110.035006_bib2) 2006; 12 Itoh (10.1124/dmd.110.035006_bib16) 1997; 236 Sakai (10.1124/dmd.110.035006_bib34) 2007; 357 Fisher (10.1124/dmd.110.035006_bib12) 2009; 37 Fisher (10.1124/dmd.110.035006_bib11) 2008; 82 Ross (10.1124/dmd.110.035006_bib33) 2004; 382 Angulo (10.1124/dmd.110.035006_bib6) 2002; 346 Czeczot (10.1124/dmd.110.035006_bib10) 2006; 53 Nakata (10.1124/dmd.110.035006_bib30) 2006; 21 Codreanu (10.1124/dmd.110.035006_bib8) 2009; 8 Kleiner (10.1124/dmd.110.035006_bib19) 2005; 41 Lickteig (10.1124/dmd.110.035006_bib20) 2007; 21 Marra (10.1124/dmd.110.035006_bib25) 2008; 14 Moffit (10.1124/dmd.110.035006_bib28) 2007; 230 Jaiswal (10.1124/dmd.110.035006_bib17) 2000; 29 Henderson (10.1124/dmd.110.035006_bib14) 2005; 401 Aleksunes (10.1124/dmd.110.035006_bib3) 2007; 35 Coles (10.1124/dmd.110.035006_bib9) 2005; 401 Lin (10.1124/dmd.110.035006_bib21) 2009; 20 Jaiswal (10.1124/dmd.110.035006_bib18) 2004; 36 Nagata (10.1124/dmd.110.035006_bib29) 2007; 32 Ali (10.1124/dmd.110.035006_bib5) 2009; 41 Lu (10.1124/dmd.110.035006_bib22) 2009; 30 van Iersel (10.1124/dmd.110.035006_bib36) 1997; 108 Nguyen (10.1124/dmd.110.035006_bib31) 2000; 275 Higashi (10.1124/dmd.110.035006_bib15) 2004; 209 Aleksunes (10.1124/dmd.110.035006_bib4) 2006; 11 Mannervik (10.1124/dmd.110.035006_bib24) 1999 Manfredi (10.1124/dmd.110.035006_bib23) 2009; 10 Hayes (10.1124/dmd.110.035006_bib13) 2005; 45 Clapper (10.1124/dmd.110.035006_bib7) 1998; 111–112 Pastore (10.1124/dmd.110.035006_bib32) 2003; 333 Martin (10.1124/dmd.110.035006_bib26) 2009; 674 Zhang (10.1124/dmd.110.035006_bib37) 2006; 38 Adams (10.1124/dmd.110.035006_bib1) 2007; 17 |
References_xml | – volume: 382 start-page: 115 year: 2004 end-page: 144 ident: bib33 article-title: NAD(P)H:quinone oxidoreductase 1 (NQO1, DT-diaphorase), functions and pharmacogenetics publication-title: Methods Enzymol – volume: 346 start-page: 1221 year: 2002 end-page: 1231 ident: bib6 article-title: Nonalcoholic fatty liver disease publication-title: N Engl J Med – volume: 38 start-page: 769 year: 2006 end-page: 789 ident: bib37 article-title: Mechanistic studies of the Nrf2-Keap1 signaling pathway publication-title: Drug Metab Rev – volume: 108 start-page: 67 year: 1997 end-page: 78 ident: bib36 article-title: Interactions of α,β-unsaturated aldehydes and ketones with human glutathione publication-title: Chem Biol Interact – volume: 209 start-page: 155 year: 2004 end-page: 163 ident: bib15 article-title: Regulatory mechanism of glutathione S-transferase P-form during chemical hepatocarcinogenesis: old wine in a new bottle publication-title: Cancer Lett – volume: 21 start-page: 437 year: 2006 end-page: 457 ident: bib30 article-title: Nuclear receptor-mediated transcriptional regulation in phase I, II, and III xenobiotic metabolizing systems publication-title: Drug Metab Pharmacokinet – volume: 230 start-page: 197 year: 2007 end-page: 206 ident: bib28 article-title: Role of NAD(P)H:quinone oxidoreductase 1 in clofibrate-mediated hepatoprotection from acetaminophen publication-title: Toxicology – volume: 35 start-page: 459 year: 2007 end-page: 473 ident: bib3 article-title: Emerging role of Nrf2 in protecting against hepatic and gastrointestinal disease publication-title: Toxicol Pathol – volume: 20 start-page: 405 year: 2009 end-page: 415 ident: bib21 article-title: GST M1 polymorphism associates with DNA oxidative damage and mortality among hemodialysis patients publication-title: J Am Soc Nephrol – year: 1999 ident: bib24 article-title: Measurement of glutathione transferases publication-title: Current Protocols in Toxicology – volume: 41 start-page: 265 year: 2009 end-page: 278 ident: bib5 article-title: New diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD) publication-title: Ann Med – volume: 82 start-page: 959 year: 2008 end-page: 964 ident: bib11 article-title: Drug metabolizing enzyme induction pathways in experimental non-alcoholic steatohepatitis publication-title: Arch Toxicol – volume: 382 start-page: 355 year: 2004 end-page: 364 ident: bib35 article-title: Role of nicotinamide quinone oxidoreductase 1 (NQO1) in protection against toxicity of electrophiles and reactive oxygen intermediates publication-title: Methods Enzymol – volume: 40 start-page: S17 year: 2006 end-page: S29 ident: bib27 article-title: Pathophysiology of nonalcoholic steatohepatitis publication-title: J Clin Gastroenterol – volume: 10 start-page: 29 year: 2009 end-page: 34 ident: bib23 article-title: Glutathione S-transferase T1- and M1-null genotypes and coronary artery disease risk in patients with type 2 diabetes mellitus publication-title: Pharmacogenomics – volume: 36 start-page: 1199 year: 2004 end-page: 1207 ident: bib18 article-title: Nrf2 signaling in coordinated activation of antioxidant gene expression publication-title: Free Radic Biol Med – volume: 14 start-page: 72 year: 2008 end-page: 81 ident: bib25 article-title: Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis publication-title: Trends Mol Med – volume: 357 start-page: 575 year: 2007 end-page: 578 ident: bib34 article-title: Regulation of glutathione transferase P: a tumor marker of hepatocarcinogenesis publication-title: Biochem Biophys Res Commun – volume: 236 start-page: 313 year: 1997 end-page: 322 ident: bib16 article-title: An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements publication-title: Biochem Biophys Res Commun – volume: 275 start-page: 15466 year: 2000 end-page: 15473 ident: bib31 article-title: Transcriptional regulation of the antioxidant response element. Activation by Nrf2 and repression by MafK publication-title: J Biol Chem – volume: 32 start-page: 453 year: 2007 end-page: 468 ident: bib29 article-title: Common pathogenic mechanism in development progression of liver injury caused by non-alcoholic or alcoholic steatohepatitis publication-title: J Toxicol Sci – volume: 401 start-page: 9 year: 2005 end-page: 42 ident: bib9 article-title: Human alpha class glutathione publication-title: Methods Enzymol – volume: 29 start-page: 254 year: 2000 end-page: 262 ident: bib17 article-title: Regulation of genes encoding NAD(P)H:quinone oxidoreductases publication-title: Free Radic Biol Med – volume: 45 start-page: 51 year: 2005 end-page: 88 ident: bib13 article-title: Glutathione transferases publication-title: Annu Rev Pharmacol Toxicol – volume: 30 start-page: 42 year: 2009 end-page: 59 ident: bib22 article-title: Regulation of glutathione synthesis publication-title: Mol Aspects Med – volume: 401 start-page: 116 year: 2005 end-page: 135 ident: bib14 article-title: Disruption of the glutathione transferase pi class genes publication-title: Methods Enzymol – volume: 12 start-page: 1937 year: 2006 end-page: 1940 ident: bib2 article-title: Up-regulation of NAD(P)H quinone oxidoreductase 1 during human liver injury publication-title: World J Gastroenterol – volume: 53 start-page: 237 year: 2006 end-page: 242 ident: bib10 article-title: Glutathione and GSH-dependent enzymes in patients with liver cirrhosis and hepatocellular carcinoma publication-title: Acta Biochim Pol – volume: 333 start-page: 19 year: 2003 end-page: 39 ident: bib32 article-title: Analysis of glutathione: implication in redox and detoxification publication-title: Clin Chim Acta – volume: 37 start-page: 2087 year: 2009 end-page: 2094 ident: bib12 article-title: Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease publication-title: Drug Metab Dispos – volume: 111–112 start-page: 377 year: 1998 end-page: 388 ident: bib7 article-title: Glutathione publication-title: Chem Biol Interact – volume: 17 start-page: 863 year: 2007 end-page: 869 ident: bib1 article-title: Nonalcoholic fatty liver disease publication-title: Ann Epidemiol – volume: 674 start-page: 93 year: 2009 end-page: 100 ident: bib26 article-title: Polymorphisms in the NQO1, GSTT and GSTM genes are associated with coronary heart disease and biomarkers of oxidative stress publication-title: Mutat Res – volume: 41 start-page: 1313 year: 2005 end-page: 1321 ident: bib19 article-title: Design and validation of a histological scoring system for nonalcoholic fatty liver disease publication-title: Hepatology – volume: 11 start-page: 356 year: 2006 end-page: 363 ident: bib4 article-title: Nuclear factor-E2-related factor 2 expression in liver is critical for induction of NAD(P)H:quinone oxidoreductase 1 during cholestasis publication-title: Cell Stress Chaperones – volume: 21 start-page: 216 year: 2007 end-page: 220 ident: bib20 article-title: Genes of the antioxidant response undergo upregulation in a rodent model of nonalcoholic steatohepatitis publication-title: J Biochem Mol Toxicol – volume: 8 start-page: 670 year: 2009 end-page: 680 ident: bib8 article-title: Global analysis of protein damage by the lipid electrophile 4-hydroxy-2-nonenal publication-title: Mol Cell Proteomics – volume: 21 start-page: 216 year: 2007 ident: 10.1124/dmd.110.035006_bib20 article-title: Genes of the antioxidant response undergo upregulation in a rodent model of nonalcoholic steatohepatitis publication-title: J Biochem Mol Toxicol doi: 10.1002/jbt.20177 – volume: 82 start-page: 959 year: 2008 ident: 10.1124/dmd.110.035006_bib11 article-title: Drug metabolizing enzyme induction pathways in experimental non-alcoholic steatohepatitis publication-title: Arch Toxicol doi: 10.1007/s00204-008-0312-z – volume: 36 start-page: 1199 year: 2004 ident: 10.1124/dmd.110.035006_bib18 article-title: Nrf2 signaling in coordinated activation of antioxidant gene expression publication-title: Free Radic Biol Med doi: 10.1016/j.freeradbiomed.2004.02.074 – volume: 21 start-page: 437 year: 2006 ident: 10.1124/dmd.110.035006_bib30 article-title: Nuclear receptor-mediated transcriptional regulation in phase I, II, and III xenobiotic metabolizing systems publication-title: Drug Metab Pharmacokinet doi: 10.2133/dmpk.21.437 – volume: 346 start-page: 1221 year: 2002 ident: 10.1124/dmd.110.035006_bib6 article-title: Nonalcoholic fatty liver disease publication-title: N Engl J Med doi: 10.1056/NEJMra011775 – volume: 40 start-page: S17 year: 2006 ident: 10.1124/dmd.110.035006_bib27 article-title: Pathophysiology of nonalcoholic steatohepatitis publication-title: J Clin Gastroenterol – volume: 29 start-page: 254 year: 2000 ident: 10.1124/dmd.110.035006_bib17 article-title: Regulation of genes encoding NAD(P)H:quinone oxidoreductases publication-title: Free Radic Biol Med doi: 10.1016/S0891-5849(00)00306-3 – volume: 674 start-page: 93 year: 2009 ident: 10.1124/dmd.110.035006_bib26 article-title: Polymorphisms in the NQO1, GSTT and GSTM genes are associated with coronary heart disease and biomarkers of oxidative stress publication-title: Mutat Res doi: 10.1016/j.mrgentox.2008.09.009 – volume: 17 start-page: 863 year: 2007 ident: 10.1124/dmd.110.035006_bib1 article-title: Nonalcoholic fatty liver disease publication-title: Ann Epidemiol doi: 10.1016/j.annepidem.2007.05.013 – volume: 8 start-page: 670 year: 2009 ident: 10.1124/dmd.110.035006_bib8 article-title: Global analysis of protein damage by the lipid electrophile 4-hydroxy-2-nonenal publication-title: Mol Cell Proteomics doi: 10.1074/mcp.M800070-MCP200 – volume: 10 start-page: 29 year: 2009 ident: 10.1124/dmd.110.035006_bib23 article-title: Glutathione S-transferase T1- and M1-null genotypes and coronary artery disease risk in patients with type 2 diabetes mellitus publication-title: Pharmacogenomics doi: 10.2217/14622416.10.1.29 – volume: 333 start-page: 19 year: 2003 ident: 10.1124/dmd.110.035006_bib32 article-title: Analysis of glutathione: implication in redox and detoxification publication-title: Clin Chim Acta doi: 10.1016/S0009-8981(03)00200-6 – volume: 209 start-page: 155 year: 2004 ident: 10.1124/dmd.110.035006_bib15 article-title: Regulatory mechanism of glutathione S-transferase P-form during chemical hepatocarcinogenesis: old wine in a new bottle publication-title: Cancer Lett doi: 10.1016/j.canlet.2004.01.003 – volume: 38 start-page: 769 year: 2006 ident: 10.1124/dmd.110.035006_bib37 article-title: Mechanistic studies of the Nrf2-Keap1 signaling pathway publication-title: Drug Metab Rev doi: 10.1080/03602530600971974 – volume: 53 start-page: 237 year: 2006 ident: 10.1124/dmd.110.035006_bib10 article-title: Glutathione and GSH-dependent enzymes in patients with liver cirrhosis and hepatocellular carcinoma publication-title: Acta Biochim Pol doi: 10.18388/abp.2006_3384 – volume: 37 start-page: 2087 year: 2009 ident: 10.1124/dmd.110.035006_bib12 article-title: Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease publication-title: Drug Metab Dispos doi: 10.1124/dmd.109.027466 – volume: 12 start-page: 1937 year: 2006 ident: 10.1124/dmd.110.035006_bib2 article-title: Up-regulation of NAD(P)H quinone oxidoreductase 1 during human liver injury publication-title: World J Gastroenterol doi: 10.3748/wjg.v12.i12.1937 – volume: 236 start-page: 313 year: 1997 ident: 10.1124/dmd.110.035006_bib16 article-title: An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements publication-title: Biochem Biophys Res Commun doi: 10.1006/bbrc.1997.6943 – volume: 45 start-page: 51 year: 2005 ident: 10.1124/dmd.110.035006_bib13 article-title: Glutathione transferases publication-title: Annu Rev Pharmacol Toxicol doi: 10.1146/annurev.pharmtox.45.120403.095857 – volume: 20 start-page: 405 year: 2009 ident: 10.1124/dmd.110.035006_bib21 article-title: GST M1 polymorphism associates with DNA oxidative damage and mortality among hemodialysis patients publication-title: J Am Soc Nephrol doi: 10.1681/ASN.2008020227 – volume: 401 start-page: 116 year: 2005 ident: 10.1124/dmd.110.035006_bib14 article-title: Disruption of the glutathione transferase pi class genes publication-title: Methods Enzymol doi: 10.1016/S0076-6879(05)01007-4 – volume: 275 start-page: 15466 year: 2000 ident: 10.1124/dmd.110.035006_bib31 article-title: Transcriptional regulation of the antioxidant response element. Activation by Nrf2 and repression by MafK publication-title: J Biol Chem doi: 10.1074/jbc.M000361200 – volume: 41 start-page: 1313 year: 2005 ident: 10.1124/dmd.110.035006_bib19 article-title: Design and validation of a histological scoring system for nonalcoholic fatty liver disease publication-title: Hepatology doi: 10.1002/hep.20701 – volume: 382 start-page: 115 year: 2004 ident: 10.1124/dmd.110.035006_bib33 article-title: NAD(P)H:quinone oxidoreductase 1 (NQO1, DT-diaphorase), functions and pharmacogenetics publication-title: Methods Enzymol doi: 10.1016/S0076-6879(04)82008-1 – volume: 14 start-page: 72 year: 2008 ident: 10.1124/dmd.110.035006_bib25 article-title: Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis publication-title: Trends Mol Med doi: 10.1016/j.molmed.2007.12.003 – volume: 230 start-page: 197 year: 2007 ident: 10.1124/dmd.110.035006_bib28 article-title: Role of NAD(P)H:quinone oxidoreductase 1 in clofibrate-mediated hepatoprotection from acetaminophen publication-title: Toxicology doi: 10.1016/j.tox.2006.11.052 – volume: 41 start-page: 265 year: 2009 ident: 10.1124/dmd.110.035006_bib5 article-title: New diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD) publication-title: Ann Med doi: 10.1080/07853890802552437 – volume: 401 start-page: 9 year: 2005 ident: 10.1124/dmd.110.035006_bib9 article-title: Human alpha class glutathione S-transferases: genetic polymorphism, expression, and susceptibility to disease publication-title: Methods Enzymol doi: 10.1016/S0076-6879(05)01002-5 – year: 1999 ident: 10.1124/dmd.110.035006_bib24 article-title: Measurement of glutathione transferases – volume: 32 start-page: 453 year: 2007 ident: 10.1124/dmd.110.035006_bib29 article-title: Common pathogenic mechanism in development progression of liver injury caused by non-alcoholic or alcoholic steatohepatitis publication-title: J Toxicol Sci doi: 10.2131/jts.32.453 – volume: 111–112 start-page: 377 year: 1998 ident: 10.1124/dmd.110.035006_bib7 article-title: Glutathione S-transferases—biomarkers of cancer risk and chemopreventive response publication-title: Chem Biol Interact doi: 10.1016/S0009-2797(97)00174-9 – volume: 35 start-page: 459 year: 2007 ident: 10.1124/dmd.110.035006_bib3 article-title: Emerging role of Nrf2 in protecting against hepatic and gastrointestinal disease publication-title: Toxicol Pathol doi: 10.1080/01926230701311344 – volume: 108 start-page: 67 year: 1997 ident: 10.1124/dmd.110.035006_bib36 article-title: Interactions of α,β-unsaturated aldehydes and ketones with human glutathione S-transferase P1-1 publication-title: Chem Biol Interact doi: 10.1016/S0009-2797(97)00096-3 – volume: 382 start-page: 355 year: 2004 ident: 10.1124/dmd.110.035006_bib35 article-title: Role of nicotinamide quinone oxidoreductase 1 (NQO1) in protection against toxicity of electrophiles and reactive oxygen intermediates publication-title: Methods Enzymol doi: 10.1016/S0076-6879(04)82019-6 – volume: 11 start-page: 356 year: 2006 ident: 10.1124/dmd.110.035006_bib4 article-title: Nuclear factor-E2-related factor 2 expression in liver is critical for induction of NAD(P)H:quinone oxidoreductase 1 during cholestasis publication-title: Cell Stress Chaperones doi: 10.1379/CSC-217.1 – volume: 30 start-page: 42 year: 2009 ident: 10.1124/dmd.110.035006_bib22 article-title: Regulation of glutathione synthesis publication-title: Mol Aspects Med doi: 10.1016/j.mam.2008.05.005 – volume: 357 start-page: 575 year: 2007 ident: 10.1124/dmd.110.035006_bib34 article-title: Regulation of glutathione transferase P: a tumor marker of hepatocarcinogenesis publication-title: Biochem Biophys Res Commun doi: 10.1016/j.bbrc.2007.03.174 |
SSID | ssj0014439 |
Score | 2.4006848 |
Snippet | Nonalcoholic fatty liver disease (NAFLD), which occurs in approximately 17 to 40% of Americans, encompasses progressive stages of liver damage ranging from... Nonalcoholic fatty liver disease (NAFLD), which occurs in approximately 17 to 40% of Americans, encompasses progressive stages of liver damage ranging from... |
SourceID | pubmedcentral proquest pubmed pascalfrancis crossref elsevier |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 2293 |
SubjectTerms | Adult Antioxidants - metabolism Biological and medical sciences Disease Progression Fatty Liver - enzymology Fatty Liver - pathology Gastroenterology. Liver. Pancreas. Abdomen Glutamate-Cysteine Ligase - analysis Glutamate-Cysteine Ligase - genetics Glutathione - metabolism Glutathione Transferase - analysis Glutathione Transferase - genetics Humans Liver. Biliary tract. Portal circulation. Exocrine pancreas Medical sciences NAD(P)H Dehydrogenase (Quinone) - analysis NAD(P)H Dehydrogenase (Quinone) - genetics NF-E2-Related Factor 2 - metabolism Other diseases. Semiology Pharmacology. Drug treatments |
Title | Diversity in Antioxidant Response Enzymes in Progressive Stages of Human Nonalcoholic Fatty Liver Disease |
URI | https://dx.doi.org/10.1124/dmd.110.035006 https://www.ncbi.nlm.nih.gov/pubmed/20805291 https://www.proquest.com/docview/808464688 https://pubmed.ncbi.nlm.nih.gov/PMC2993454 |
Volume | 38 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb5swFLay7mXSNO3e7FL5YeoeUjIwJsBjlaSqujbqplTKG8I2pEgJjdJEWvur9xN2jI1xukTa-gIRGKxwvs8-xz4XhL6kPGeCep6Thzx0aEZih-WuAF4JCrOlAC1V7uhejHqnV_RsEkxard-W19J6xbr8fmtcyWOkCtdArjJK9j8ka14KF-A3yBeOIGE4_pOMB8apQq5aSL_FX4WATyUX5aXna9YZlvd388rnSoYEVLa1dBUCFXOqss2qRfyR1MerWrkF75ykK3jjuXy3TM5p9m-0CjtYrqey8DSgZ1ZX2BCF8f5qhrSlqMu0_7wGEJaAs1HX4MWUXO8v02LaGZg7_bTMTBhR58xcP0-VH9HxYlnM6vZ6veIv349xEzBTbnimXjapulXmqaFd4mDcRKPZi5hu7DpxEOhk2noIJ54DNyb2GO9HNpaJPWITVaFRz_5gkXnbZxZCAQ5iLmTgRFfux1aZElYWzBbzCmfElWUiVA2yB7m8Ly_6MP37NKBP0FMCho0cmb__aPa9KPWVwab_l04zCp1_2-xaJrHW_ezSqJ4v0lvgea4KtGyzoB46Alua1fgleqFNInys8P0KtbLyNTrUgro7wrZQjvAhtkX4BhWGBLgosUUCXJMAaxLI-xYJsCIBvslxRQJskwBXJMAVCbAmwVt0dTIc908dXT_E4bQXrRzOXOrzmPQiH04sjkMhgjjlcRTHJOUwGqV-wODMQ8Gom_eikAWpjDX3fEpz4b9De8CNbB9hElLG8rDn5aGgPhVxlHs88yMB5jsDNbiNnFoGCdfJ9WWNl1lSGdmEJiA--OEmSnxt9NW0X6i0MjtberVIE60UK2U3AWTufOZgQ_amC-IHYH5E0ADXYEhgOpF7hMDtm_VtErlgkMDXi9rovcJG87DGWxuFG6gxDWSm-s07ZXFdZazXoP_w6Cc_omfNWPIJ7a2W6-wzWAMrdlAR6A-qZxDi |
linkProvider | Colorado Alliance of Research Libraries |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Diversity+in+Antioxidant+Response+Enzymes+in+Progressive+Stages+of+Human+Nonalcoholic+Fatty+Liver+Disease&rft.jtitle=Drug+metabolism+and+disposition&rft.au=Hardwick%2C+Rhiannon+N.&rft.au=Fisher%2C+Craig+D.&rft.au=Canet%2C+Mark+J.&rft.au=Lake%2C+April+D.&rft.date=2010-12-01&rft.pub=The+American+Society+for+Pharmacology+and+Experimental+Therapeutics&rft.issn=0090-9556&rft.eissn=1521-009X&rft.volume=38&rft.issue=12&rft.spage=2293&rft.epage=2301&rft_id=info:doi/10.1124%2Fdmd.110.035006&rft_id=info%3Apmid%2F20805291&rft.externalDocID=PMC2993454 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0090-9556&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0090-9556&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0090-9556&client=summon |